Abstract

QUETIAPINE FUMARATE: A SUSTAIN RELEASE FORMULATION FOR SCHIZOPHRENIA AND BIPOLAR DISORDER

Singh Prerana* and Gnanarajan G.

ABSTRACT

Schizophrenia is a persistent, progressive psychogenic disorder that affects the sociological psychological behaviour of a human body. It can be the most chronic and incapacitate. Schizophrenia is a psychogenic malady characterized by change in perception between real and virtual figures. Quetiapine Fumarate (QF) is a cure that works counteract schizophrenic symptoms. It is a second generation antipsychotic (SGA) or atypical antipsychotic drug. QF rebalances dopamine and serotonin by blocking the dopamine and serotonin receptors to ameliorate thinking, mood, and behavior. The impetus of the present work was to devise sustained release tablets of QF using polymer Hydroxy propyl methyl cellulose (HPMC) (K-4M and K-100M) and its polymer methocil (K-4M and K-100M). Distinct ratios of API, excipients and polymers were elected for the preparation. Three different batches were prepared, after mending the ratio of API and polymer to codify sustain release tablets. HPMC polymer is utilized to endure the release of drug up to desired time, the release rates were modulated by different rate controlling material. Physical parameters of tablets were evaluated, pre-compression mixture was evaluated for flow ability and compressibility.Study of pre-compression powder formulation showed that these powder formulation were within the theoretical range for processing into tablet dosage form. Afterwards vitro drug release study was observed in 0.1N HCL pH 1.2 for 2 hours and in phosphate buffer pH 6.8 up to 24 hours which confirms that the drug release was sustained up to 12 hours.

Keywords: Quetiapine Fumarate(QF), Hydroxy propyl methyl cellulose(HPMC), Schizophrenia, Sustained release, active pharmaceutical ingredient (API).